The present invention relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention.Izolovano antitelo, ili jedan od njegovih dvovalentnih fragmenata za vezivanje c-Met, naznačen time što antitelo sadrži težak lanac koji sadrži CDR-H1, CDR-H2 i CDR-H3 koji sadrži, respektivno, aminokiselinsku sekvencu SEQ ID Nos. 1, 2 i 3； i lak lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 koji sadrži, respektivno, aminokiselinsku sekvencu SEQ ID Nos. 10, 11 i 12. Prijava sadrži još 21 patentnih zahteva.
